PS6 expression in normal renal parenchyma, primary renal cell carcinomas and their metastases

Pathology and Oncology Research

Volumn 18, Issue 2, 2012, Pages 277-283

  Hager, Martina ^a   Haufe, Heike ^a   Alinger, Beate ^a   Kolbitsch, Christian ^b  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Kidney cancer; Metastases; Normal renal parenchyma; pS6; Renal cell carcinoma

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE LOCATION; GENE OVEREXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; METASTASIS; OVERALL SURVIVAL; PRIMARY TUMOR; SURVIVAL TIME; TISSUE DISTRIBUTION; TISSUE MICROARRAY;

CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RIBOSOMAL PROTEIN S6; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 84863425080     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9439-y     Document Type: Article

References (26)

1. Dufner A, Thomas G (1999) Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 253:100-109
2. Ferrari S, Bandi HR, Hofsteenge J et al (1991) Mitogen-activated 70K S6 kinase. Identification of in vitro 40 S ribosomal S6 phosphorylation sites. J Biol Chem 266:22770-22775
3. Bose S, Chandran S, Mirocha JM et al (2006) The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 19:238-245
4. Cho D, Signoretti S, Dabora S et al (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Canc 5:379-385
5. Chow S, Minden MD, Hedley DW (2006) Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. Exp Hematol 34:1183-1191
6. Cotler SJ, Hay N, Xie H et al (2008) Immunohistochemical expression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease. Dig Dis Sci 53:844-849
7. Iwenofu OH, Lackman RD, Staddon AP et al (2008) Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 21:231-237
8. Pantuck AJ, Seligson DB, Klatte T et al (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109:2257-2267
9. Robb VA, Karbowniczek M, Klein-Szanto AJ et al (2007) Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 177:346-352
10. Trinh XB, Tjalma WA, Vermeulen PB et al (2009) The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Canc 100:971-978
11. Fresno Vara JA, Casado E, De Castro J et al (2004) PI3K/Akt signalling pathway and cancer. Canc Treat Rev 30:193-204
12. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Gene Dev 18:1926-1945
13. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med 356:2271-2281
14. Kapoor A, Figlin RA (2009) Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 115:3618-3630
15. Merseburger AS, Kuczyk MA (2008) Value of targeted therapies for renal cell cancer. Urologe A 47:1303-1310
16. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-663
17. Eble JN, Sauter G, Epstein JI et al (2004) WHO classification of tumours. Tumors of the urinary system and male genital organs. IARC, Lyon, pp 23-34
18. Campbell L, Jasani B, Edwards K et al (2008) Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Canc 98:931-940
19. Klatte T, Seligson DB, La Rochelle J et al (2009) Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Canc Epidemiol Biomarkers Prev 18:894-900
20. Amato RJ, Jac J, Giessinger S et al (2009) A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115:2438-2446
21. Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918
22. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456
23. Patel PH, Chadalavada RS, Chaganti RS et al (2006) Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Canc Res 12:7215-7220
24. Akcakanat A, Sahin A, Shaye AN et al (2008) Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer 112:2352-2358
25. Ljungberg B, Cowan NC, Hanbury DC et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398-406
26. Youssif TA, Fahmy MA, Koumakpayi IH et al (2011) The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 117:290-300